Figure 2.
OS and hematologic CR to daratumumab-based therapies in newly diagnosed and relapsed/refractory systemic AL amyloidosis.

OS and hematologic CR to daratumumab-based therapies in newly diagnosed and relapsed/refractory systemic AL amyloidosis.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal